Lipocine Inc. (LPCN)

US — Healthcare Sector

Peers: SGTX RVPH ZVSA KRBP UNCY CKPT MBIO FBIOP KOD ARDX ZURA HEPA AVRO VSTM RVPHW EYEN CGTX RNAZ

Automate Your Wheel Strategy on LPCN

With Tiblio's Option Bot, you can configure your own wheel strategy including LPCN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

symbol LPCN
Rev/Share 0.6871
Book/Share 3.5898
PB 0.8697
Debt/Equity 0.0
CurrentRatio 15.64
ROIC -0.3369

MktCap 16703824.0
FreeCF/Share -1.0635
PFCF -2.9366
PE -3.1095
Debt/Assets 0.0
DivYield 0
ROE -0.2668

Rating C
Score 2
Recommendation Sell
P/E Score 1
DCF Score 3
P/B Score 4
D/E Score 1

Recent Analyst Ratings

Type	Ticker	Analyst Firm	Previous Rating	Current Rating	Previous Price Target	Current Price Target	Date
No ratings available.

News

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

LPCN
Published: May 22, 2025 by: PRNewsWire
Sentiment: Neutral

SALT LAKE CITY , May 22, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that its development candidate LPCN 1148 for men with cirrhosis is featured in the "Hepatology Highlights" section of the June 2025 edition of Hepatology. The article "LPCN 1148: Rebuilding muscle memory in cirrhosis patients" was contributed by Dr. Kevin Harris of the Division of Gastroenterology and Hepatology, Mayo Clinic, Minnesota.

image for news Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

LPCN
Published: March 26, 2025 by: PRNewsWire
Sentiment: Neutral

48 hour at-home dosing Patient dosing expected in Q2/2025 SALT LAKE CITY , March 26, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced the initiation of a Phase 3 trial for LPCN 1154 (oral brexanolone) which is in development for the treatment of postpartum depression (PPD). Based on observed comparable exposure of LPCN 1154 and the reference drug established in the pharmacokinetic (PK) bridge study, the company is initiating a phase 3 safety and efficacy study with expected first patient dosed in the second …

image for news Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

About Lipocine Inc. (LPCN)

IPO Date 2013-10-22
Website https://www.lipocine.com
Industry Biotechnology
CEO Dr. Mahesh V. Patel Ph.D.
Employees 16

Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.